Compare ClearPoint Neuro Inc (CLPT) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Verisign, Inc. — how do they compare? ClearPoint Neuro Inc trades at $15.22 (market cap $454.21M), while Verisign, Inc. trades at $288.99 (market cap $26.00B). The key difference: Verisign, Inc. is far larger — about 57.2× ClearPoint Neuro Inc's market cap, and Verisign, Inc. pays a 1.13% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | VRSN | |
|---|---|---|
Market Cap | $454.21M | $26.00B |
Sector | Health | Technology |
52-Week High | $29.60 | $310.00 |
52-Week Low | $8.66 | $211.49 |
Enterprise Value | $488.79M | $27.31B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
VeriSign (VRSN) trades at $282.94, down 3.55% over the past day, with a mixed earnings history including a recent Q2 2026 EPS miss. The stock shows a bullish technical trend with strong moving averages, while fundamentals highlight robust profitability with a net income margin near 50% and revenue growth to $1.66B in 2025. Recent news emphasizes record domain registrations and the delegation of the .web domain, supporting growth outlook.
The outlook remains positive with a consensus price target of $320, reflecting 13% upside, driven by AI-fueled domain demand and pricing power. Risks include contract renewals and high debt levels, but analyst sentiment is bullish with 60% buy ratings. The stock presents a growth opportunity with manageable execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
